{
"id":"mk19_a_on_q069",
"number":69,
"bookId":"on",
"correctAnswer":"A",
"title":"Question 69",
"stimulus":[
{
"type":"p",
"hlId":"e7a4b2",
"children":[
"A 47-year-old man is evaluated during a follow-up examination. His medical history is significant for resection of cutaneous malignant melanoma from his left upper back 4 years ago. One month ago, he was diagnosed with metastatic melanoma to the liver and lungs. He takes no medications."
]
},
{
"type":"p",
"hlId":"e35a8c",
"children":[
"No mutation in the liver metastasis ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" gene was identified."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"8e8a00",
"children":[
"Which of the following is the most appropriate treatment for this patient?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Anti-CTLA-4 antibody plus anti–programmed death antibody"
}
},
{
"letter":"B",
"text":{
"__html":"<i>BRAF</i> inhibitor"
}
},
{
"letter":"C",
"text":{
"__html":"Combination of a <i>BRAF</i> and <i>MEK</i> inhibitor"
}
},
{
"letter":"D",
"text":{
"__html":"<i>MEK</i> inhibitor"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"e343f2",
"children":[
"Immunotherapy with an anti–CTLA-4 antibody plus an anti-programmed death antibody improves response rates compared with either agent alone and is the preferred treatment for patients with metastatic melanoma without a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation."
]
},
{
"type":"keypoint",
"hlId":"aebc80",
"children":[
"In a patient with metastatic melanoma with a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation, treatment with either immunotherapy or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"-targeted therapy is appropriate."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"e2896e",
"children":[
"This patient has ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF-"
]
},
"nonmutated melanoma, and the best treatment is immunotherapy with an anti–CTLA-4 antibody plus an anti–programmed death (anti–PD-1) antibody (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Ipilimumab is an anti–CTLA-4 antibody, and nivolumab is an anti–PD-1 antibody. Individually, they each have activity against malignant melanoma. Ipilimumab has a response rate as a single agent of 10% to 15%. Nivolumab and other anti–PD-1 antibodies, such as pembrolizumab, have a response rate of about 40%. The combination is more active than either drug alone, although it is associated with more immune toxicities. This immunotherapy combination is effective whether the melanoma is ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutated or not. Some of these responses are quite durable with a minority of patients remaining free of recurrence for many years."
]
},
{
"type":"p",
"hlId":"0a9931",
"children":[
"Although about 50% of melanomas have a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation (most commonly ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" V600E or V600K), the other half of melanomas do not. Patients who have a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation may respond to therapy with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" inhibitors (vemurafenib, dabrafenib, and encorafenib) along with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibitors (trametinib, cobimetinib, and binimetinib). However, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" inhibitors are not effective in patients with tumors such as this one that is not ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutated (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). Thus, there is no role for the use of a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" inhibitor in this patient who lacks a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation. Other driver mutations identified in patients with melanoma include ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"NRAS"
]
},
" and c-KIT."
]
},
{
"type":"p",
"hlId":"6b021c",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibitors (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") do have single-agent activity in melanoma but are usually used in combination with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" inhibitors. Adding a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibitor to a BRAF inhibitor improves the response rate and the durability of response in ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"-mutated melanoma. A ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibitor combined with a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" inhibitor (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated in this patient with a tumor that lacks a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"-related mutation. Finally, treatment with an anti–CTLA-4 antibody plus an anti–PD-1 antibody results in superior clinical outcomes compared to treatment with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibitor monotherapy."
]
},
{
"type":"p",
"hlId":"1d5baa",
"children":[
"In a patient with metastatic disease who has a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
" mutation, treatment with either immunotherapy or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"-targeted therapy would be appropriate without a clear indication as of yet which treatment is superior. In patients who are ill and in need of a rapid response or in those with underlying autoimmune disorders who would be at increased risk for adverse immune-related events, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRAF"
]
},
"/",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEK"
]
},
" inhibition may be favored, given the potential for more rapid response and the lower rate of autoimmune complications."
]
}
],
"relatedSection":"mk19_a_on_s11_1",
"objective":{
"__html":"Treat <i>BRAF-</i>nonmutated melanoma with immunotherapy."
},
"references":[
[
"Bomar L, Senithilnathan A, Ahn C. Systemic therapies for advanced melanoma. Dermatol Clin. 2019;37:409-23. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31466582",
"target":"_blank"
},
"children":[
"PMID: 31466582"
]
},
" doi:10.1016/j.det.2019.05.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":60,
"B":6,
"C":25,
"D":10,
"E":0
},
"hlIds":[
"e7a4b2",
"e35a8c",
"8e8a00",
"e343f2",
"aebc80",
"e2896e",
"0a9931",
"6b021c",
"1d5baa"
]
}